Testing new drugs is a slow and expensive process. AI has the potential to disrupt clinical trials — from patient recruitment to adherence monitoring and data collection — and Covid-19 has catalyzed its adoption.
From basic testing to clinical trials, here’s how LabCorp is being unbundled.
Reeling from Covid-19’s widespread disruption, healthcare players are turning to partnerships to strengthen their clinical trial capabilities. We use CB Insights Business Relationships data to analyze what this signals about the future of clinical trials.
Business Model Analysis
Evidation aims to fill in the gaps of traditional clinical trial outcomes with novel health datasets via its digital research platform. In this post, we analyze Evidation’s funding, business model, customer acquisition strategy, market size, and competitors.
With Covid-19 throwing clinical trial speed into the spotlight, we dive into the new innovations — like "organ-on-a-chip" tech and digital twins — enabling researchers to design better-informed, more efficient studies.
Clinical trials may become more efficient as emerging tech transforms processes like study management, patient recruitment, and more. We look at how the clinical trial landscape is changing.
Big tech incumbents are moving into healthcare, tackling the many gaps in this industry. And their recent efforts suggest that revamping the pharma sector may be one of their top priorities. We take a closer look at these initiatives.
There are a lot of bottlenecks throughout clinical trials, which can keep patients from finding or enrolling in the right trials, and keep researchers from sourcing enough eligible patients. Below, we explore the startups looking to disrupt this market and highlight the emerging tech here.
In 2018, there were a string of failures related to key Alzheimer's drug trials. We explore the pharma players that are still actively pursuing potential treatments and how they plan to leverage partnerships to advance their respective drug candidates.